BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y, Whaley A, Pinnelli M, Murciano-Goroff YR, Vakiani E, Valeri N, Liao WL, Bhalkikar A, Thyparambil S, Zhao HY, de Stanchina E, Marsoni S, Siena S, Bertotti A, Trusolino L, Li BT, Rosen N, Di Nicolantonio F, Bardelli A, Misale S. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discov 2020;10:1129-39. [PMID: 32430388 DOI: 10.1158/2159-8290.CD-20-0187] [Cited by in Crossref: 50] [Cited by in F6Publishing: 29] [Article Influence: 25.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang B, Zhang Y, Zhang J, Liu P, Jiao B, Wang Z, Ren R. Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK-YAP Signaling. Adv Sci (Weinh) 2021;8:e2100250. [PMID: 34151545 DOI: 10.1002/advs.202100250] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol 2021;18:506-25. [PMID: 33864051 DOI: 10.1038/s41571-021-00495-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Akhave NS, Biter AB, Hong DS. Mechanisms of Resistance to KRASG12C-Targeted Therapy. Cancer Discov 2021;11:1345-52. [PMID: 33820777 DOI: 10.1158/2159-8290.CD-20-1616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
5 Krishnan T, Roberts-Thomson R, Broadbridge V, Price T. Targeting Mutated KRAS Genes to Treat Solid Tumours. Mol Diagn Ther 2021. [PMID: 34914038 DOI: 10.1007/s40291-021-00564-0] [Reference Citation Analysis]
6 Gmeiner WH. Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development. Onco Targets Ther 2021;14:2121-30. [PMID: 33790575 DOI: 10.2147/OTT.S242224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Naim N, Moukheiber S, Daou S, Kourie HR. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies. Crit Rev Oncol Hematol 2021;168:103524. [PMID: 34800654 DOI: 10.1016/j.critrevonc.2021.103524] [Reference Citation Analysis]
8 Pfeiffer P, Qvortrup C. KRASG12C inhibition in colorectal cancer. Lancet Oncol 2022;23:10-1. [PMID: 34919826 DOI: 10.1016/S1470-2045(21)00652-5] [Reference Citation Analysis]
9 Ponsioen B, Post JB, Buissant des Amorie JR, Laskaris D, van Ineveld RL, Kersten S, Bertotti A, Sassi F, Sipieter F, Cappe B, Mertens S, Verlaan-Klink I, Boj SF, Vries RGJ, Rehmann H, Vandenabeele P, Riquet FB, Trusolino L, Bos JL, Snippert HJG. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling. Nat Cell Biol 2021;23:377-90. [PMID: 33795873 DOI: 10.1038/s41556-021-00654-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
10 Cheng WL, Feng PH, Lee KY, Chen KY, Sun WL, Van Hiep N, Luo CS, Wu SM. The Role of EREG/EGFR Pathway in Tumor Progression. Int J Mol Sci 2021;22:12828. [PMID: 34884633 DOI: 10.3390/ijms222312828] [Reference Citation Analysis]
11 Stein MK, Oluoha O, Patel K, VanderWalde A. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. J Pers Med 2021;11:518. [PMID: 34198738 DOI: 10.3390/jpm11060518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 2022;23:115-24. [PMID: 34919824 DOI: 10.1016/S1470-2045(21)00605-7] [Reference Citation Analysis]
13 Kim D, Xue JY, Lito P. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell 2020;183:850-9. [PMID: 33065029 DOI: 10.1016/j.cell.2020.09.044] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
14 Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev 2021;35:787-820. [PMID: 34074695 DOI: 10.1101/gad.348226.120] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yu C, Luo D, Yu J, Zhang M, Zheng X, Xu G, Wang J, Wang H, Xu Y, Jiang K, Xu J, Ma X, Jing J, Shi H. Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer. Oncogene 2021. [PMID: 34718347 DOI: 10.1038/s41388-021-02077-w] [Reference Citation Analysis]
16 Wang C, Fakih M. Targeting KRAS in Colorectal Cancer. Curr Oncol Rep 2021;23:28. [PMID: 33582927 DOI: 10.1007/s11912-021-01022-0] [Reference Citation Analysis]
17 Mauri G, Durinikova E, Amatu A, Tosi F, Cassingena A, Rizzetto F, Buzo K, Arcella P, Aquilano MC, Bonoldi E, Marsoni S, Siena S, Bardelli A, Sartore-Bianchi A, Arena S. Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. JCO Precis Oncol 2021;5:PO. [PMID: 34327296 DOI: 10.1200/PO.21.00143] [Reference Citation Analysis]
18 Dai S, Xu S, Ye Y, Ding K. Identification of an Immune-Related Gene Signature to Improve Prognosis Prediction in Colorectal Cancer Patients. Front Genet 2020;11:607009. [PMID: 33343640 DOI: 10.3389/fgene.2020.607009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Adhikari H, Kattan WE, Kumar S, Zhou P, Hancock JF, Counter CM. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. Nat Commun 2021;12:5248. [PMID: 34504076 DOI: 10.1038/s41467-021-25523-5] [Reference Citation Analysis]
20 Rizzo G, Bertotti A, Leto SM, Vetrano S. Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer. J Exp Clin Cancer Res 2021;40:178. [PMID: 34074330 DOI: 10.1186/s13046-021-01970-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Ros J, Baraibar I, Martini G, Salvà F, Saoudi N, Cuadra-Urteaga JL, Dienstmann R, Tabernero J, Élez E. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Curr Treat Options Oncol 2021;22:113. [PMID: 34741675 DOI: 10.1007/s11864-021-00913-5] [Reference Citation Analysis]
22 Bellio H, Fumet JD, Ghiringhelli F. Targeting BRAF and RAS in Colorectal Cancer. Cancers (Basel) 2021;13:2201. [PMID: 34063682 DOI: 10.3390/cancers13092201] [Reference Citation Analysis]
23 Durinikova E, Buzo K, Arena S. Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges. J Exp Clin Cancer Res 2021;40:185. [PMID: 34090508 DOI: 10.1186/s13046-021-01981-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Molina-Arcas M, Samani A, Downward J. Drugging the Undruggable: Advances on RAS Targeting in Cancer. Genes (Basel) 2021;12:899. [PMID: 34200676 DOI: 10.3390/genes12060899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Imyanitov E, Kuligina E. Molecular testing for colorectal cancer: Clinical applications. World J Gastrointest Oncol 2021; 13(10): 1288-1301 [PMID: 34721767 DOI: 10.4251/wjgo.v13.i10.1288] [Reference Citation Analysis]
26 Zhang J, Zhang J, Liu Q, Fan XX, Leung EL, Yao XJ, Liu L. Resistance looms for KRAS G12C inhibitors and rational tackling strategies. Pharmacol Ther 2021;229:108050. [PMID: 34864132 DOI: 10.1016/j.pharmthera.2021.108050] [Reference Citation Analysis]
27 Dunnett-Kane V, Nicola P, Blackhall F, Lindsay C. Mechanisms of Resistance to KRASG12C Inhibitors. Cancers (Basel) 2021;13:E151. [PMID: 33466360 DOI: 10.3390/cancers13010151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
28 Cimino SK, Eng C. Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer. J Exp Pharmacol 2020;12:475-85. [PMID: 33204182 DOI: 10.2147/JEP.S259287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Merz V, Gaule M, Zecchetto C, Cavaliere A, Casalino S, Pesoni C, Contarelli S, Sabbadini F, Bertolini M, Mangiameli D, Milella M, Fedele V, Melisi D. Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Front Oncol 2021;11:638360. [PMID: 33777798 DOI: 10.3389/fonc.2021.638360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Luo J. KRAS mutation in pancreatic cancer. Semin Oncol 2021:S0093-7754(21)00008-7. [PMID: 33676749 DOI: 10.1053/j.seminoncol.2021.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Chen K, Zhang Y, Qian L, Wang P. Emerging strategies to target RAS signaling in human cancer therapy. J Hematol Oncol 2021;14:116. [PMID: 34301278 DOI: 10.1186/s13045-021-01127-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer 2021;20:143. [PMID: 34742312 DOI: 10.1186/s12943-021-01441-4] [Reference Citation Analysis]
33 Bender G, Fahrioglu Yamaci R, Taneri B. CRISPR and KRAS: a match yet to be made. J Biomed Sci 2021;28:77. [PMID: 34781949 DOI: 10.1186/s12929-021-00772-0] [Reference Citation Analysis]
34 Marmorino F, Boccaccino A, Germani MM, Falcone A, Cremolini C. Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. Cancers (Basel). 2020;12. [PMID: 32824490 DOI: 10.3390/cancers12082317] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
35 Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Oncol 2021;5:PO. [PMID: 34250391 DOI: 10.1200/PO.20.00256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Serna-Blasco R, Sánchez-Herrero E, Sanz-Moreno S, Rodriguez-Festa A, García-Veros E, Casarrubios M, Sierra-Rodero B, Laza-Briviesca R, Cruz-Bermúdez A, Mielgo-Rubio X, Sánchez-Hernández A, Uribelarrea EA, Calvo V, Romero A, Provencio M. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor. ESMO Open 2021;6:100279. [PMID: 34607284 DOI: 10.1016/j.esmoop.2021.100279] [Reference Citation Analysis]
37 Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther 2021;6:386. [PMID: 34776511 DOI: 10.1038/s41392-021-00780-4] [Reference Citation Analysis]
38 Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 2020;383:1207-17. [PMID: 32955176 DOI: 10.1056/NEJMoa1917239] [Cited by in Crossref: 203] [Cited by in F6Publishing: 121] [Article Influence: 101.5] [Reference Citation Analysis]
39 Nagayama S, Low SK, Kiyotani K, Nakamura Y. Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. Cancers (Basel) 2021;13:4803. [PMID: 34638288 DOI: 10.3390/cancers13194803] [Reference Citation Analysis]
40 Ning W, Yang Z, Kocher GJ, Dorn P, Peng R. A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished. Cancers 2022;14:390. [DOI: 10.3390/cancers14020390] [Reference Citation Analysis]
41 Cheng DK, Oni TE, Thalappillil JS, Park Y, Ting HC, Alagesan B, Prasad NV, Addison K, Rivera KD, Pappin DJ, Van Aelst L, Tuveson DA. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Proc Natl Acad Sci U S A 2021;118:e2016904118. [PMID: 34021083 DOI: 10.1073/pnas.2016904118] [Reference Citation Analysis]